Cholesterol Drug Pelacarsen Fails in Heart Health Trial

Pelacarsen's Disappointing Results

An experimental drug known as pelacarsen, developed by Novartis, has failed to demonstrate any benefit in preventing heart attacks or strokes in a recent clinical trial. Researchers expressed their shock at the unexpected results, which have been termed a significant setback for the field of preventive cardiology.

Trial Insights

The findings were presented at the American Heart Association's annual meeting, revealing that the drug did not lead to any measurable reductions in stroke, heart attacks, deaths from cardiovascular issues, or necessary procedures for unblocking arteries. Dr. Amanda Doran, an assistant professor of medicine at Vanderbilt University Medical Center, was one of many researchers caught off guard by these results. "I really thought that this was going to be a slam dunk," she stated.

Pelacarsen targets lipoprotein(a), commonly referred to as Lp(a), a genetically influenced substance that can lead to artery plaque formation and blood clotting. Despite its role as a dangerous cholesterol type, affecting nearly 20% of Americans, many individuals remain unaware of their elevated risks.

Trial Details and Outcomes

The Horizon trial encompassed 8,322 participants with high Lp(a) who had previously experienced heart-related issues. While the drug successfully reduced Lp(a) levels by 78% compared to a placebo's 13% reduction, these figures did not translate into improved cardiovascular health outcomes.

Dr. Steven Nissen, who led the trial at the Cleveland Clinic, was particularly surprised by the results. "Everybody, me included, believed that lowering levels of lipoprotein(a) substantially would reduce the risk of major cardiovascular events," he remarked. Despite the significant decrease in Lp(a) levels, there was no evidence suggesting that those individuals experienced better outcomes.

Understanding Lp(a)

Experts have proposed several theories to explain the unexpected failure of pelacarsen. One suggestion is that participants may have received treatment too late in life to see substantial benefits. With an average participant age of 60 and a follow-up of roughly five years, the timing may not have been optimal for the genetic risk posed by Lp(a).

Furthermore, aggressive treatment methods involving other cholesterol and blood pressure medications could have masked any potential benefits from lowering Lp(a). Dr. Karol Watson from UCLA noted, "How much of the Lp(a)-associated risk was remaining? We just don’t know." This uncertainty leads researchers to continue advocating for Lp(a) screenings, as high levels can still indicate an increased risk of cardiovascular issues.

The Future of Lp(a) Treatments

Despite the discouraging results with pelacarsen, there is hope on the horizon. Several other drugs targeting Lp(a) are under development, including Eli Lilly’s lepodisiran and Amgen’s olpasiran, which employ different approaches by blocking the liver's production of Lp(a). These new treatments promise to provide alternatives to pelacarsen, with clinical trials currently underway to evaluate their impact on heart health.

Overall, while pelacarsen's outcome may be disheartening, experts agree Lp(a) remains a crucial marker for heart disease risk. Dr. John Wilkins from Northwestern Medicine emphasizes that testing for Lp(a) can identify patients at higher risk of cardiovascular events, allowing earlier interventions. As the understanding of Lp(a) and its treatment evolves, the quest to find effective solutions continues unabated.